Immuron Ltd IMRN
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
Immuron Ltd (IMRN) is a healthcare company listed in the US with a market value of about $7M. In fiscal year 2025 it had revenue of $5M and net income of -$3M, a net margin of -71.6%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 22% a year, a 5-year average ROIC of -28%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.
About Immuron
Immuron is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. Revenue went from $744461 in 2016 to $5M in 2025, growth of about 22.9% a year. It was profitable in 0 of the last 10 years in our data.
Score: 2.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $3M | $1M | $526412 | $109277 | $2M | $2M | $1M | $1M | $744461 |
| Net income | -$3M | -$5M | -$3M | -$2M | -$6M | -$2M | -$3M | -$2M | -$5M | -$5M |
| Free cash flow | — | -$4M | -$2M | -$2M | -$3M | -$2M | -$1M | -$3M | -$5M | -$4M |
| EPS (diluted) | $-0.42 | $-0.57 | $-0.31 | $-0.24 | $-0.78 | $-0.25 | $-0.40 | $-0.28 | $-0.65 | $-0.65 |
| Net margin | -71.6% | -141.5% | -209.8% | -373.0% | -5751.6% | -116.2% | -195.0% | -166.5% | -487.3% | -706.1% |
| ROIC | -52.3% | -36.1% | -14.4% | -9.8% | -25.6% | -40.7% | -50.0% | -28.5% | -79.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Immuron stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Immuron pay a dividend?
Not currently.
Is Immuron a good stock to buy?
We do not give buy or sell advice. Immuron scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.